Is Inventiva S.A. (IVA) a Buy, Sell, or Hold?
Inventiva S.A.
NASDAQ:IVA
$4.47 USD
$0.07 (1.59%)
- Volume
- 984.82K
- Average Volume
- 835.87K
- Market Capitalization
- $232.36M
- P/E Ratio
- -2.04
- Dividend Yield
- 0.00%
- Price Target
- $21.00
- Year High
- $7.98
- Year Low
- $2.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.16
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Andrew Obenshain |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IVA |
| CUSIP | 46124U107 |
| CIK | 0001756594 |
| Web | https://www.inventivapharma.com |
| Phone | 33 3 80 44 75 00 |
| Currency | USD |
| Employees | 77 |
| Country | FR |
Liquidity
| Debt-to-Equity Ratio | -2.10 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.16 |
| Quick Ratio | 3.16 |
| Cash Ratio | 1.28 |
Sales & Book Value
| Annual Sales | $4.48M |
| Price / Sales | 120.05 |
| Cash Flow | -0.17 |
| Price / Cash Flow | -5.11 |
| Price / Book | -86.44 |
Price Target and Rating
| Average Stock Price Forecast | $21.00 |
| High Stock Price Forecast | $24.00 |
| Low Stock Price Forecast | $18.00 |
| Forecast Upside/Downside | -78.71% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.82 |
| Trailing P/E Ratio | -2.04 |
| PEG Ratio | -0.15 |
| P/E Growth | -0.15 |
| Net Income | $-340.16M |
| Net Margin | -7899.58% |
| Pretax Margin | -7949.86% |
| Return on Equity | 1870.38% |
| Return on Assets | -141.93% |
Financials Score
| AltmanZ Score | -6.26 |
| Piotroski Score | 3.00 |
| Working Capital | 166.49M |
| Total Assets | 248.88M |
| Ebit | -418.2M |
| Market Cap | 195.94M |
| Total Liabilities | 277.91M |
Poll Results
About Inventiva S.A. (NASDAQ:IVA) Stock
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic ... areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
2026-07-09 16:20:00
Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the “Combined Transaction”) through the issuance of approximately 15.7 million new warrants (bons de souscription d'actions) (the "New EIB Warrants") to the European Investment Bank (the "EIB") and the surrender and cancellation of all remaining warrants originally issued to the EIB in January 2024 (the “Legacy EIB Tranche B Warrants”) that were not repurchased in the Combined Transaction.
Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026
2026-07-02 16:00:00
Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders' Meeting.
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
2026-06-29 10:36:04
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Claret Capital Partners participates in €130m financing for Inventiva
2026-06-16 05:12:33
Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASH Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing Latest in a series of late stage, European biotech investments by Claret Capital as part of its expansion in life sciences London, 16 June, 2026, Claret Capital Partners ('Claret'), Europe's largest independent growth debt fund manager has made an investment through its funds, of €43m in Inventiva (Euronext Paris and NASDAQ: IVA), a clinical-stage biopharmaceutical company developing an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), a common and progressive chronic liver disease.
Claret Capital Partners participates in €130m financing for Inventiva
2026-06-16 05:12:00
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
2026-06-16 04:52:00
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing, to support its lead asset through Phase 3.
2026-06-12 16:00:00
Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the completion, on June 12, 2026, of the following key steps of the transactions previously announced on June 2, 2026 (the “Combined Transaction”): (i) the repayment in full of the EIB Loans and the repurchase of a portion of the existing EIB Warrants; and (ii) the issuance of the Tranche A Convertible Bonds and the Tranche B Amortized Bonds, together with the Lenders' Warrants, under the Debt Financing Transaction for net proceeds of €71,298,750.
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
2026-06-11 10:36:06
The heavy selling pressure might have exhausted for Inventiva (IVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Frequently Asked Questions
-
What is the current Inventiva S.A. (IVA) stock price?
-
Inventiva S.A.(NASDAQ:IVA) stock price is $4.47 in the last trading session. During the trading session, IVA stock reached the peak price of $7.983 while $2.854 was the lowest point it dropped to. The percentage change in IVA stock occurred in the recent session was 1.59% while the dollar amount for the price change in IVA stock was $0.07.
-
IVA's industry and sector of operation?
-
The NASDAQ listed IVA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IVA?
-
Andrew Obenshain | Chief Executive Officer
Jason A. Campagna | President of Research & Development and Chief Medical Officer
Nazira Amra | Chief Commercial Strategy Officer
Pascaline Clerc | Executive Vice President of External and Corporate Affairs
Susan Coles | Chief Legal Officer -
How many employees does IVA have?
-
Number of IVA employees currently stands at 77. IVA operates from 50 rue de Dijon, Daix, BF 21121, FR.
-
Link for IVA official website?
-
Official Website of IVA is: https://www.inventivapharma.com
-
How do I contact IVA?
-
IVA could be contacted at phone #33 3 80 44 75 00 and can also be accessed through its website. IVA operates from 50 rue de Dijon, Daix, BF 21121, FR.
-
How many shares of IVA are traded daily?
-
The average number of IVA shares traded daily for last 3 months was 835.87K.
-
What is the market cap of IVA currently?
-
The market value of IVA currently stands at $232.36M with its latest stock price at $4.47